BR112012006069A8 - Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto - Google Patents

Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto

Info

Publication number
BR112012006069A8
BR112012006069A8 BR112012006069A BR112012006069A BR112012006069A8 BR 112012006069 A8 BR112012006069 A8 BR 112012006069A8 BR 112012006069 A BR112012006069 A BR 112012006069A BR 112012006069 A BR112012006069 A BR 112012006069A BR 112012006069 A8 BR112012006069 A8 BR 112012006069A8
Authority
BR
Brazil
Prior art keywords
opioid
compound
treating
human
effective amount
Prior art date
Application number
BR112012006069A
Other languages
English (en)
Other versions
BR112012006069A2 (pt
Inventor
M Woodward Richard
Original Assignee
Adolor Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012006069(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adolor Corp, Merck Sharp & Dohme filed Critical Adolor Corp
Publication of BR112012006069A2 publication Critical patent/BR112012006069A2/pt
Publication of BR112012006069A8 publication Critical patent/BR112012006069A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MÉTODO PARA TRATAR OU PREVENIR CONSTIPAÇÃO INDUZIDA E DISFUNÇÃO INTESTINAL INDUZIDA POR OPIÓIDE EM UM HUMANO, E, USO DE UMA QUANTIDADE TERAPEUTICAMENTE 5 EFETIVA DE COMPOSTO A revelação refere-se a um método de tratar ou prevenir uma condição em um sujeito associada com a ativação de um receptor opiÓide na periferia pela administração de uma quantidade efetiva de 5-(2-metóxi-4-{ [2- (tetra-hidro-piran-4-il)-etil-amino]-metil}-fenóxi)-pirazina-2-carboxamida 10 (Composto I). Em particular, a revelação refere-se a um método de tratar ou prevenir constipação induzida por opióide ou disfúnção intestinal induzida por opióide em um humano sem reduzir analgesia de opióide centralmente mediada ou produzir sintomas de supressão de opióide central pela administração de um-a quantidade efetiva de Composto (I). A revelação 15 adicionalmente se refere ao uso de Composto (I) para a preparação de um medicamento para o tratamento ou a prevenção de uma condição em um sujeito associada com a ativação de um receptor opióide na periferia.
BR112012006069A 2009-09-18 2010-09-17 Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto BR112012006069A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (2)

Publication Number Publication Date
BR112012006069A2 BR112012006069A2 (pt) 2016-03-29
BR112012006069A8 true BR112012006069A8 (pt) 2017-10-10

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006069A BR112012006069A8 (pt) 2009-09-18 2010-09-17 Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto

Country Status (19)

Country Link
US (1) US20110071163A1 (pt)
EP (1) EP2477627B1 (pt)
JP (1) JP5797655B2 (pt)
KR (1) KR20120092592A (pt)
CN (2) CN102695508A (pt)
AU (1) AU2010295464B2 (pt)
BR (1) BR112012006069A8 (pt)
CA (1) CA2774021A1 (pt)
CL (1) CL2012000676A1 (pt)
CO (1) CO6531453A2 (pt)
HK (1) HK1210959A1 (pt)
IL (1) IL218679A0 (pt)
MX (1) MX342548B (pt)
NZ (1) NZ598783A (pt)
PE (1) PE20120991A1 (pt)
RU (1) RU2561873C2 (pt)
TW (1) TW201118084A (pt)
WO (1) WO2011035142A1 (pt)
ZA (1) ZA201201954B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027856T2 (en) 2012-12-28 2016-11-28 Inst Medycyny Doswiadczalnej I Klinicznej Im Miroslawa Mossakowskiego Polskiej Akademii Nauk Peptidomimetics and their use
AU2017265377A1 (en) 2016-05-20 2018-11-22 Esteve Pharmaceuticals, S.A. Tetrahydropyran and Thiopyran derivatives having multimodal activity against pain
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP1252896B1 (en) 1994-04-22 2007-03-21 Astellas Pharma Inc. Colon-specific drug release system
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
ES2171839T3 (es) * 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO2000018377A1 (en) 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
MXPA02003756A (es) * 1999-10-15 2005-09-08 Sucampo Ag Composicion novedosa y metodo para estabilizar la misma.
EP1225897B1 (en) * 1999-11-01 2004-09-08 RHODES, John Composition for treatment of constipation and irritable bowel syndrome
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
AU2002330747B2 (en) * 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
DK1436012T3 (en) * 2001-10-18 2018-01-22 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
DK1562595T3 (da) * 2002-09-19 2008-08-18 Lilly Co Eli Diarylethere som opioidreceptorantagonister
TWI336254B (en) * 2002-12-27 2011-01-21 Sucampo Ag Pharmaceutical composition for treating abdominal discomfort
AU2004220113A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
CA2549009A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
BRPI0417714A (pt) * 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
US7381750B2 (en) * 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
DK1978944T3 (da) * 2006-01-24 2012-11-05 Sucampo Ag Blød-gelatine-kapselformulering
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
CN101896455B (zh) * 2007-12-11 2015-04-29 施万生物制药研发Ip有限责任公司 作为mu阿片类受体拮抗剂的3-羧基丙基-氨基四氢萘衍生物
RU2512390C2 (ru) * 2008-12-10 2014-04-10 Тереванс, Инк. Кристаллические формы соединения 3-карбоксипропил-аминотетралина
PT2506712T (pt) * 2009-12-04 2019-05-31 Alkermes Pharma Ireland Ltd Derivados de morfinano para o tratamento da overdose por fármaco

Also Published As

Publication number Publication date
RU2012115450A (ru) 2013-10-27
EP2477627B1 (en) 2018-08-15
AU2010295464A1 (en) 2012-04-12
KR20120092592A (ko) 2012-08-21
MX2012003310A (es) 2012-07-17
EP2477627A1 (en) 2012-07-25
ZA201201954B (en) 2012-11-28
MX342548B (es) 2016-10-04
CN102695508A (zh) 2012-09-26
NZ598783A (en) 2013-07-26
HK1210959A1 (en) 2016-05-13
IL218679A0 (en) 2012-05-31
TW201118084A (en) 2011-06-01
JP5797655B2 (ja) 2015-10-21
PE20120991A1 (es) 2012-08-01
CO6531453A2 (es) 2012-09-28
CA2774021A1 (en) 2011-03-24
US20110071163A1 (en) 2011-03-24
CL2012000676A1 (es) 2012-10-19
WO2011035142A1 (en) 2011-03-24
RU2561873C2 (ru) 2015-09-10
AU2010295464B2 (en) 2015-11-26
BR112012006069A2 (pt) 2016-03-29
CN104958298A (zh) 2015-10-07
JP2013505260A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
MY160894A (en) Oligosaccharide composition for treating skin diseases
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2012003102A (es) Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos.
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
MX356965B (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX2013005095A (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma.
MX2009009153A (es) Pirano-pirazol-aminas.
MX2012011631A (es) Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
BR112012006069A8 (pt) Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
MX2009008176A (es) Derivados de tetrahidro-naftaleno sustituidos con heterociclos, su preparacion y su uso como medicamentos.
EP2464355A4 (en) SUBSTITUTED TRIAZOLPHTHALAZINE DERIVATIVES

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME CORP (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]